20 scheduled drug formulations cleared for discontinuation amid weak demand and competition

The National Pharmaceutical Pricing Authority has approved 20 Form-IV intimations for discontinuation of scheduled formulations for FY 2025-26. The reasons cited include low or no market demand, declining market share, availability of competing products, portfolio optimisation and difficulties in sourcing APIs.

Join our 1500+ subscribers to get our daily Health Laws and Policy Updates.